Quest Continues to Extend Reach of Immunotherapy, PARP Inhibitors in Ovarian Cancer
Published: Wednesday, Jul 17, 2019
Matthew Powell, MD
Single-agent immunotherapy has elicited minimal responses in patients with ovarian cancer, but the preclinical rationale for combinations with chemotherapy, antivascular therapy, and PARP inhibitors is strong and worthy of further pursuit, said Matthew Powell, MD.
... to read the full story